Equities

Apyx Medical Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Apyx Medical Corp

Actions
  • Price (EUR)3.36
  • Today's Change0.14 / 4.35%
  • Shares traded1.05k
  • 1 Year change+156.49%
  • Beta1.5805
Data delayed at least 15 minutes, as of Feb 10 2026 07:04 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Apyx Medical, Inc., formerly Apyx Medical Corporation, is a surgical aesthetics company. Its segments include Advanced Energy and Original Equipment Manufacturer (OEM). The Advanced Energy segment’s product portfolio consists of its Helium Plasma Technology that is marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. It focuses on the cosmetic surgery market, where Renuvion offers plastic surgeons, facial plastic surgeons and cosmetic physicians the ability to provide controlled heat to the tissue to achieve their desired results. These product lines consist of a multifunction generator, a handpiece and a supply of helium gas. Through OEM agreements, the OEM segment, designs, develops and manufactures electrosurgical equipment and medical devices by producing generators, medical devices and related accessories for medical device manufacturers as well as start-up businesses in need of its energy-based designs.

  • Revenue in USD (TTM)47.90m
  • Net income in USD-14.54m
  • Incorporated1982
  • Employees220.00
  • Location
    Apyx Medical Corp5115 Ulmerton RoadCLEARWATER 33760United StatesUSA
  • Phone+1 (727) 384-2323
  • Fax+1 (631) 421-5821
  • Websitehttps://apyxmedical.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.